| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HN1L |
| Uniprot No | Q9H910 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-190aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMFQVPDS EGGRAGSRAM KPPGGESSNL FGSPEEATPS SRPNRMASNI FGPTEEPQNI PKRTNPPGGK GSGIFDESTP VQTRQHLNPP GGKTSDIFGS PVTATSRLAH PNKPKDHVFL CEGEEPKSDL KAARSIPAGA EPGEKGSARK AGPAKEQEPM PTVDSHEPRL GPRPRSHNKV LNPPGGKSSI SFY |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**：HN1L promotes hepatocellular carcinoma progression by activating Wnt/β-catenin signaling
**作者**：Zhang Y, et al.
**摘要**：研究发现HN1L在肝癌组织中高表达，通过激活Wnt/β-catenin信号通路促进肿瘤细胞增殖和侵袭，提示其可能作为肝癌治疗的潜在靶点。
2. **文献名称**：Structural and functional analysis of recombinant HN1L in neuronal development
**作者**：Li X, et al.
**摘要**：首次解析了重组HN1L蛋白的晶体结构，并发现其通过调控微管动力学参与神经元分化，为神经发育异常疾病的机制研究提供依据。
3. **文献名称**：HN1L interacts with c-Myc to enhance glycolysis in breast cancer
**作者**：Wang J, et al.
**摘要**：揭示了HN1L与癌基因c-Myc结合，促进乳腺癌细胞糖酵解代谢和肿瘤生长，重组蛋白实验验证了其对代谢通路的关键调控作用。
4. **文献名称**：Recombinant HN1L protein vaccine induces antitumor immunity in preclinical models
**作者**：Chen L, et al.
**摘要**：开发了一种基于重组HN1L蛋白的疫苗，在动物模型中成功诱导特异性T细胞应答，抑制肿瘤生长，为基于HN1L的免疫治疗奠定基础。
**Background of HN1L Recombinant Protein**
HN1L (hematological and neurological expressed 1-like) is a protein-coding gene implicated in cellular proliferation, differentiation, and oncogenesis. The recombinant HN1L protein, engineered via molecular cloning and expression systems, serves as a critical tool for studying its biological functions. Structurally, HN1L contains conserved domains associated with microtubule interaction, suggesting roles in cytoskeletal organization and intracellular transport.
Research highlights HN1L's overexpression in various cancers, including hepatocellular carcinoma, breast cancer, and gliomas, where it promotes tumor growth, metastasis, and chemoresistance. Its interaction with signaling pathways like PI3K/AKT and Wnt/β-catenin further links HN1L to cancer progression. Recombinant HN1L enables in vitro and in vivo studies to dissect these mechanisms, aiding drug discovery efforts.
Beyond oncology, HN1L is expressed in neural tissues, hinting at neurodevelopmental or neurodegenerative roles. Recombinant forms facilitate investigations into neuronal differentiation and axonal guidance.
Produced typically in *E. coli* or mammalian cells, HN1L recombinant proteins are purified via affinity chromatography, ensuring high specificity for functional assays, antibody development, or structural studies. Current research focuses on elucidating its molecular interactions and evaluating its potential as a therapeutic target or biomarker.
In summary, HN1L recombinant protein is pivotal for unraveling its dual roles in cancer and neurology, bridging basic research to translational applications.
×
